FOXA1 is a determinant of drug resistance in breast cancer cells

[1]  Jeff S. Jasper,et al.  The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer , 2019, Cell reports.

[2]  M. Gnant,et al.  Breast cancer , 2019, Nature Reviews Disease Primers.

[3]  T. Sørlie,et al.  Re-definition of claudin-low as a breast cancer phenotype , 2019, bioRxiv.

[4]  M. Gottesman,et al.  Revisiting the role of ABC transporters in multidrug-resistant cancer , 2018, Nature Reviews Cancer.

[5]  R. Weinberg,et al.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.

[6]  M. Asaduzzaman,et al.  Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer , 2017, Breast Cancer Research and Treatment.

[7]  K. Kaestner,et al.  Fox transcription factors: from development to disease , 2016, Development.

[8]  Laura M. Heiser,et al.  FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer , 2016, Proceedings of the National Academy of Sciences.

[9]  I. Bednarek,et al.  The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells , 2016, Cancer biology & therapy.

[10]  L. weiswald,et al.  Spherical Cancer Models in Tumor Biology1 , 2015, Neoplasia.

[11]  L. Mir,et al.  The Culture of Cancer Cell Lines as Tumorspheres Does Not Systematically Result in Cancer Stem Cell Enrichment , 2014, PloS one.

[12]  S. Vowler,et al.  Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype , 2013, Oncogene.

[13]  S. Raguz,et al.  The miR-106b∼25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300 , 2013, Cell Death and Differentiation.

[14]  Jan J. Brosens,et al.  Forkhead box proteins: tuning forks for transcriptional harmony. , 2013, Nature reviews. Cancer.

[15]  Jindan Yu,et al.  Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. , 2013, Cancer research.

[16]  Raphaël Porcher,et al.  Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15 , 2013, Breast Cancer Research.

[17]  Jeffrey T. Chang,et al.  FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. , 2013, Cancer research.

[18]  S. Raguz,et al.  Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. , 2013, Biochemical pharmacology.

[19]  Paul J Hertzog,et al.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape , 2012, Nature Medicine.

[20]  Gurkan Bebek,et al.  FOXA1 Represses the Molecular Phenotype of Basal Breast Cancer Cells , 2012, Oncogene.

[21]  I. Ellis,et al.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.

[22]  A. Brodie,et al.  Adaptive Changes Result in Activation of Alternate Signaling Pathways and Acquisition of Resistance to Aromatase Inhibitors , 2011, Clinical Cancer Research.

[23]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[24]  J. Carroll,et al.  FOXA1 is a critical determinant of Estrogen Receptor function and endocrine response , 2010, Nature Genetics.

[25]  H. Gómez,et al.  Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone , 2010, Breast Cancer Research.

[26]  Zhiwei Wang,et al.  Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[27]  R. Coombes,et al.  Inhibition of γ-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells , 2009, British Journal of Cancer.

[28]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[29]  E. Lander,et al.  Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. , 2008, Cancer research.

[30]  E. Lam,et al.  The emerging roles of forkhead box (Fox) proteins in cancer , 2007, Nature Reviews Cancer.

[31]  S. Raguz,et al.  Role of the highly structured 5'-end region of MDR1 mRNA in P-glycoprotein expression. , 2007, The Biochemical journal.

[32]  Charles M Perou,et al.  FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival , 2007, Clinical Cancer Research.

[33]  E. Lam,et al.  Induction of Mxi1-SRα by FOXO3a Contributes to Repression of Myc-Dependent Gene Expression , 2007, Molecular and Cellular Biology.

[34]  A. Feinberg,et al.  Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells , 2007, Molecular Cancer Therapeutics.

[35]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[36]  T. Chao,et al.  Regulatory mechanisms controlling human E-cadherin gene expression , 2005, Oncogene.

[37]  S. Raguz,et al.  Activation of the MDR1 Upstream Promoter in Breast Carcinoma as a Surrogate for Metastatic Invasion , 2004, Clinical Cancer Research.

[38]  S. Raguz,et al.  P-glycoprotein (MDR1) Expression in Leukemic Cells Is Regulated at Two Distinct Steps, mRNA Stabilization and Translational Initiation* , 2003, The Journal of Biological Chemistry.

[39]  B. Hackett.  Fox Transcription Factors , 2002 .

[40]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[41]  S. Baylin,et al.  Role of Estrogen Receptor Gene Demethylation and DNA Methyltransferase·DNA Adduct Formation in 5-Aza-2′deoxycytidine-induced Cytotoxicity In Human Breast Cancer Cells* , 1997, The Journal of Biological Chemistry.

[42]  Shao-Chun Wang,et al.  FOXA1 transcriptionally up-regulates cyclin B1 expression to enhance chondrosarcoma progression. , 2018, American journal of cancer research.

[43]  Matthew Berland,et al.  The disease , 2005, Netherlands Journal of Plant Pathology.

[44]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.